Education
About Us
Working with TipRanks
Follow Us
Vaxart Inc (VXRT)
NASDAQ:VXRT
Earnings Data
Report Date
Aug 07, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.09Last Year’s EPS
-0.09Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 13, 2025
|% Change Since: 0.00%
|Next Earnings Date:Aug 07, 2025
Earnings Call Sentiment|Neutral
The earnings call presented several positive developments, including significant revenue growth, progress in clinical trials, and promising preclinical results. However, these were balanced by challenges such as workforce reductions, CFO resignation, and the risk of NASDAQ delisting. The sentiment is balanced by both achievements and significant challenges.Company Guidance
During the Vaxart Business Update and First Quarter 2025 Financial Results Conference Call, guidance was provided on multiple fronts. The company announced that it is actively screening patients for its Project NextGen Phase 2b COVID-19 vaccine trial, with dosing expected to begin in the second quarter of 2025. This trial is supported by a BARDA contract worth up to $460.7 million. Additionally, Vaxart completed enrollment in a Phase 1 trial for its norovirus vaccine, with top-line data anticipated in mid-2025. Financially, the company reported a revenue increase to $20.9 million for Q1 2025, up from $2.2 million in Q1 2024, primarily due to the BARDA contract. Vaxart ended the quarter with $41.9 million in cash and expects its cash runway to extend into Q1 2026, despite recent workforce reductions aimed at cost rationalization. The company is also exploring strategic partnerships and non-dilutive funding to maintain its financial position while navigating the biotech environment.Revenue Increase
Revenue for the first quarter of 2025 was $20.9 million, compared to $2.2 million for the first quarter of 2024, primarily due to the BARDA contract.
Lifting of Stop Work Order
The stop work order on the 10,000 participant portion of the COVID-19 Phase 2b clinical trial was lifted, allowing the trial to proceed.
Norovirus Vaccine Trial Progress
Completed enrollment of the Phase 1 trial for the second-generation norovirus vaccine candidate, with top-line data expected mid-2025.
Positive Preclinical Results in Avian Flu Program
Preclinical studies show 100% protection against death in a ferret model for the avian flu vaccine candidate.
---
VXRT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
VXRT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 13, 2025 | $0.42 | $0.40 | -4.76% |
Mar 20, 2025 | $0.57 | $0.52 | -8.77% |
Nov 13, 2024 | $0.71 | $0.63 | -11.27% |
Aug 08, 2024 | $0.63 | $0.58 | -7.94% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Vaxart Inc (VXRT) report earnings?
Vaxart Inc (VXRT) is schdueled to report earning on Aug 07, 2025, TBA Not Confirmed.
What is Vaxart Inc (VXRT) earnings time?
Vaxart Inc (VXRT) earnings time is at Aug 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is VXRT EPS forecast?
VXRT EPS forecast for the fiscal quarter 2025 (Q2) is -0.09.
---